---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-22-017667"
form_type: "8-K"
ticker: "ORMP"
cik: "0001176309"
company_name: "ORAMED PHARMACEUTICALS INC."
filed_at: "2022-04-04T23:59:59+00:00"
generated_at: "2026-06-26T09:42:29.355998+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Oramed Pharmaceuticals appoints Yadin Rozov to board of directors

## Summary
- Board size increased by one and Yadin Rozov appointed effective April 1, 2022.
- Rozov has over 20 years experience in capital markets, corporate finance, and investment banking.
- He is founder and managing partner of Terrace Edge Ventures LLC since January 2022.
- Rozov previously served as Partner at GoldenTree Asset Management and CEO of Syncora Guarantee.
- He will receive the same compensation as other non-executive directors.

## SEC filing metadata
- accession: 0001213900-22-017667
- form_type: 8-K
- ticker: ORMP
- cik: 0001176309
- company_name: ORAMED PHARMACEUTICALS INC.
- filed_at: 2022-04-04T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1176309/000121390022017667/0001213900-22-017667-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1176309/000121390022017667/ea157933-8k_oramedphar.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-22-017667
- JSON: https://secwatch.observer/filing/0001213900-22-017667.json
- Plain text: https://secwatch.observer/filing/0001213900-22-017667.txt

## Key facts
- Executive change
  Yadin Rozov was appointed as director at ORAMED PHARMACEUTICALS INC..
  - Action: appointed
  - Role: director
  source text: On March 30, 2022, Oramed Pharmaceuticals Inc. (the “Company”) increased the size of its Board of Directors (the “Board”) by one and appointed Mr. Yadin Rozov to serve as a director to fill the resulting vacancy, effective as of April 1, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1176309/000121390022017667/0001213900-22-017667-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.